Document is current
Any future updates will be listed below
-
Authors
Pollock, Nijole C.
Ramroop, Johnny R.
Hampel, Heather
Troester, Melissa A.
Conway, Kathleen
Hu, Jennifer J.
Freudenheim, Jo L.
Olopade, Olufunmilayo I.
Huo, Dezheng
Ziv, Elad
Neuhausen, Susan L.
Stevens, Patrick
McElroy, Joseph Paul
Toland, Amanda Ewart https://orcid.org/0000-0002-0271-1792
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (R01 CA215151)
Foundation for the National Institutes of Health (P30 CA016058)
Foundation for the National Institutes of Health (CA58223)
Foundation for the National Institutes of Health (P20 CA233307)
Foundation for the National Institutes of Health (P20 CA233307)
Foundation for the National Institutes of Health (R01 MD01352)
Foundation for the National Institutes of Health (R01 MD01352)
Foundation for the National Institutes of Health (R01 CA184585)
Foundation for the National Institutes of Health (R01 CA184585)
Foundation for the National Institutes of Health (P30 CA033572)
Pelotonia Foundation
- License Information
-
More Information
Article History
Received: 7 May 2021
Accepted: 2 January 2022
First Online: 14 March 2022
Declarations
:
: HH is on the scientific advisory board for Invitae Genetics, Promega, and Genome Medical and has stock/stock options in Genome Medical and GI OnDemand. None of these are direct conflicts with this study of somatic <i>TP53</i> mutations in breast cancer.
: This study was approved by the OSU Cancer Institutional Review Board. The City of Hope Institutional Review Board and the University of Chicago IRB approved study for participants enrolled at their respective sites.
: Participants with previously unpublished data provided informed consent for this study. The remainder of data was de-identified and from publicly available databases or publications.
: Not applicable.
